Pharmaceutical

Risk adjusted net present value: What is the current valuation of Johnson & Johnson’s PN-235?

PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).

Mar 13, 2024 - 18:29
PN-235 is a synthetic peptide commercialized by Johnson & Johnson, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Risk adjusted net present value: What is the current valuation of Novo Nordisk’s...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: A seemingly small semantic issue is a major roadblock to develop treatments for rare diseases

Opinion: A seemingly small semantic issue is a major ro...

Jun 28, 2023

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Likelihood of Approval

SGNB-7H4V by Pfizer for Epithelial Ovarian Cancer: Like...

Jun 20, 2024

STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?

STAT+: What does America’s crackdown on Chinese firms m...

Feb 29, 2024